Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 8/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.54 |
| ▸ | KIT | P10721 | 2/20 | 0.54 |
| ▸ | FLT3 | P36888 | 2/20 | 0.54 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | BACE1 | P56817 | 2/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24391608 | 0.83 | ENPP1 (0.67) | ENPP1MAPK1PDGFRBPDGFRAKIT | |
| SCHEMBL4965169 | 0.79 | ENPP1 (0.61) | ENPP1MAPK1PDGFRBPDGFRAKIT | |
| SCHEMBL3068444 | 0.79 | ADRB2 (0.48) | KIT | |
| Buquineran SCHEMBL783795 | 0.77 | ENPP1 (0.60) | ENPP1MAPK1PDGFRBPDGFRAACHE | |
| SCHEMBL22441440 | 0.77 | ENPP1 (0.67) | ENPP1MAPK1ACHEBACE1PDE10A | |
| SCHEMBL5070354 | 0.77 | ENPP1 (0.61) | ENPP1MAPK1PDGFRBACHEBACE1 | |
| SCHEMBL7276486 | 0.77 | ENPP1 (0.59) | ENPP1MAPK1PDGFRBPDGFRAKIT | |
| Hydrochloric Acid SCHEMBL10798406 | 0.76 | ENPP1 (0.58) | ENPP1MAPK1PDGFRBPDGFRAKIT | |
| SCHEMBL4966150 | 0.76 | PDGFRB (0.70) | ENPP1PDGFRBPDGFRAKITFLT3 | |
| SCHEMBL20771444 | 0.75 | ENPP1 (0.65) | ENPP1MAPK1PDGFRBACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKB2, NFKBIA, NFRKB | ENPP1 3709/4885MAPK1 1515/4885PDGFRB 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.